Zobrazeno 1 - 10 of 117 pro vyhledávání: '"H Van Hoogstraten"'
1
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
3
P665 Social Media Listening to better Understand the Lived Experience of Individuals With Ulcerative Colitis
Autor: O Auriat, L Lucats, S Badalamenti, A Kruger, M Wiekowski, L Glotfelty, H Van Hoogstraten, C Coulouvrat
Publikováno v: Journal of Crohn's and Colitis. 17:i797-i797
Background Lived experience is a depiction of a person's experiences and decisions, as well as the knowledge gained from these experiences and choices. Despite a wealth of clinical studies and real-world data on ulcerative colitis, large-scale and co
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::362d0fa76df0387bf5bc76854df9792e
https://doi.org/10.1093/ecco-jcc/jjac190.0795
Zobrazit plný text záznamu
5
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
6
THU0162 LIKELIHOOD OF CLINICAL WORSENING AMONG RHEUMATOID ARTHRITIS PATIENTS WHO ACHIEVED A PARTIAL RESPONSE TO ADALIMUMAB AND WERE SUBSEQUENTLY SWITCHED TO SARILUMAB
Autor: K. Ford, H. Leher, Daniel Aletaha, Karthinathan Thangavelu, V.P. Bykerk, G.-R. Burmester, H. van Hoogstraten, Jeffrey R. Curtis
Publikováno v: Annals of the Rheumatic Diseases. 79:296.1-296
Background:Rheumatoid arthritis (RA) patients who achieve a response to therapy but fail to reach low disease activity (LDA) or remission (partial responders) may decline treatment changes for fear of clinical worsening and losing their achieved resp
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::23dc0ea69c043bb35075505fb2c6b711
https://doi.org/10.1136/annrheumdis-2020-eular.1729
Zobrazit plný text záznamu
7
SAT0102 NONINFLAMMATORY PAIN IS A FREQUENT PHENOMENON IN RHEUMATOID ARTHRITIS AND RESPONDS WELL TO TREATMENT WITH SARILUMAB
Autor: A. Praestgaard, V.P. Bykerk, H. van Hoogstraten, Anthony Sebba, E.H. Choy, K. Ford, G. St John, Yvonne C. Lee
Publikováno v: Annals of the Rheumatic Diseases. 79:984.1-985
Background:Inflammation is clearly a key driver of pain in rheumatoid arthritis (RA). However, in some patients the level of pain exceeds what would be expected based on the amount of synovitis observed, which may indicate the presence of noninflamma
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0369064f751a8371c03b12f5785cf5c7
https://doi.org/10.1136/annrheumdis-2020-eular.2015
Zobrazit plný text záznamu
8
AB0301 SARILUMAB AS MONOTHERAPY OR IN COMBINATION WITH CONVENTIONAL SYNTHETIC DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS: 12-WEEK TREATMENT RESULTS FROM A MULTICENTER, OPEN-LABEL, PROSPECTIVE, SINGLE-ARM OBSERVATIONAL STUDY
Autor: Chunfu Qiu, Martin J. Bergman, Louis Bessette, Jacques-Eric Gottenberg, G. St John, Melitza Iglesias-Rodriguez, H. van Hoogstraten, A. Kivitz
Publikováno v: Annals of the Rheumatic Diseases. 79:1450.1-1450
Background:Due to strict inclusion/exclusion criteria, randomized controlled trials (RCTs) may not represent the heterogeneous rheumatoid arthritis (RA) population encountered in routine clinical practice; longitudinal observational studies are neede
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::29cccb8cbcd0c57d45064f28450cfcaa
https://doi.org/10.1136/annrheumdis-2020-eular.1972
Zobrazit plný text záznamu
9
THU0167 ASSOCIATIONS BETWEEN RHEUMATOID ARTHRITIS DISEASE ACTIVITY AND PATIENT-REPORTED OUTCOMES IN SARILUMAB CLINICAL TRIALS
Autor: Mark C. Genovese, Twj Huizinga, H. van Hoogstraten, Roy Fleischmann, G.-R. Burmester, G. St John, A. Praestgaard, Laure Gossec, Daniel Aletaha
Publikováno v: Annals of the Rheumatic Diseases. 79:299-299
Background:Sarilumab is a human interleukin (IL)-6 receptor inhibitor approved for the treatment of adults with moderately to severely active rheumatoid arthritis (RA). The relationship between disease activity (DA), sarilumab treatment, and improvem
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::684bb6497f1ddd21be49313d2615f430
https://doi.org/10.1136/annrheumdis-2020-eular.1977
Zobrazit plný text záznamu
10
THU0215 Efficacy of sarilumab in patients with rheumatoid arthritis with and without previous response to tocilizumab
Autor: E.K. Mangan, A.A. den Broeder, H. van Hoogstraten, Patrick Verschueren, Paul Emery, Q. Dong
Publikováno v: THURSDAY, 14 JUNE 2018.
Background Sarilumab is an IL-6R inhibitor recently approved for the treatment of rheumatoid arthritis (RA). To help clinical decision making, we studied the response rate on open-label sarilumab treatment in patients previously treated with tocilizu
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f2981b983eaca1734aa7763694dc024d
https://doi.org/10.1136/annrheumdis-2018-eular.1376
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje